GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...
The growth of the DEE treatment market can be attributed to the increasing prevalence of developmental and epileptic ...
The growth of the Chronic Hepatitis B Virus Testing market can be attributed to several key factors, including significant ...
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.50. The company’s shares opened today at ...
Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on October 9. Graham ...
This content was published on Oct 26, 2024 The Swiss Federal Democratic Union (EDU) has handed in referendum signatures to seek a vote to prevent the Eurovision Song Contest (ESC) from taking ...
Last week, GlaxoSmithKline and Northwestern University filed separate lawsuits against Moderna, accusing its mRNA-based vaccines of ...
Despite strong cash flow and organic growth in most of its key brands, high leverage and mixed valuation ratios lead to a ...
Today, Cerebras Systems, the pioneer in high performance AI compute, smashed its previous industry record for inference, delivering 2,100 tokens/second performance on Llama 3.2 70B. This is 16x faster ...
Hosted on MSN3d
GSK’s Arexvy Vaccine Shows Promise for Broader UseGlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...
North Carolina is a leading place for biotech, and a big part of that success comes from GlaxoSmithKline (GSK). This global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback